{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:40:44Z","timestamp":1789062044072,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-026-00726-y","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:50:38Z","timestamp":1773809438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of zanubrutinib versus ibrutinib in the first-line treatment for patients with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in China"],"prefix":"10.1186","volume":"16","author":[{"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"20","key":"726_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"726_CR2","unstructured":"Hematology Committee of Chinese Medical Association; Hematological Oncology Committee of China Anti-Cancer Association; Chinese Working Group for Chronic Lymphocytic Leukemia. The guidelines for diagnosis and treatment of chronic lymphocytic leukemia\/small lymphocytic lymphoma in China (2022). Chin J Hematol. 2022;43(5)."},{"issue":"3","key":"726_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.blre.2014.12.001","volume":"29","author":"SM Yang","year":"2015","unstructured":"Yang SM, Li JY, Gale RP, Huang XJ. The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell Us about etiology, pathogenesis and biology? Blood Rev. 2015;29(3):205\u201313.","journal-title":"Blood Rev"},{"key":"726_CR4","unstructured":"International Agency for Research on Cancer (IARC). Available from: https:\/\/gco.iarc.fr\/2023."},{"issue":"02","key":"726_CR5","first-page":"111","volume":"11","author":"X Li","year":"2012","unstructured":"Li X, Li G, Gao Z. Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases. J Diagn Concepts Pract. 2012;11(02):111\u20135.","journal-title":"J Diagn Concepts Pract"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.leukres.2018.08.011","volume":"73","author":"S Yang","year":"2018","unstructured":"Yang S, Gale RP, Shi H, Liu Y, Lai Y, Lu J, et al. Is there an epidemic of chronic lymphocytic leukaemia (CLL) in china? Leuk Res. 2018;73:16\u201320.","journal-title":"Leuk Res"},{"key":"726_CR7","volume-title":"Clinical guidelines for the diagnosis and treatment of lymphoma, 2024","author":"The Chinese society of clinical oncology guidelines committee. The Chinese Society of Clinical Oncology (CSCO)","year":"2024","unstructured":"The Chinese society of clinical oncology guidelines committee. The Chinese Society of Clinical Oncology (CSCO). Clinical guidelines for the diagnosis and treatment of lymphoma, 2024. Beijing: People\u2019s Health Publishing House; 2024."},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.12878","volume":"1358","author":"U Gayko","year":"2015","unstructured":"Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, et al. Development of the Bruton\u2019s tyrosine kinase inhibitor ibrutinib for B cell malignancies. Ann N Y Acad Sci. 2015;1358:82\u201394.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"726_CR9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.1337","volume":"7","author":"X Huang","year":"2018","unstructured":"Huang X, Qiu L, Jin J, Zhou D, Chen X, Hou M, et al. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med. 2018;7(4):1043\u201355.","journal-title":"Cancer Med"},{"issue":"12","key":"726_CR10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363.","journal-title":"Am J Hematol"},{"issue":"1","key":"726_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9(1):80.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"726_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus Bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol"},{"issue":"4","key":"726_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"726_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40273-023-01346-8","volume":"42","author":"DW Kang","year":"2024","unstructured":"Kang DW, Wang L, Short NJ, Ferrajoli A, Wang Y, Zhou S, et al. Cost effectiveness of zanubrutinib versus ibrutinib in relapsed or refractory chronic lymphocytic leukemia. Pharmacoeconomics. 2024;42(4):409\u201318.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"726_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/14737167.2023.2288683","volume":"24","author":"R Li","year":"2024","unstructured":"Li R, Wang C, Ye Z, Chen Y, Xu J, Chen C, et al. A Markov model-based cost-effectiveness analysis comparing zanubrutinib to ibrutinib for treating relapsed and refractory chronic lymphocytic leukemia. Expert Rev Pharmacoecon Outcomes Res. 2024;24(9):1089\u201396.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"11","key":"726_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.clinthera.2024.08.016","volume":"46","author":"J Nie","year":"2024","unstructured":"Nie J, Liu L, Wu H, Yuan S, Tang K, Wu J. Cost-effectiveness of zanubrutinib versus bendamustine and rituximab in patients with untreated chronic lymphocytic leukemia. Clin Ther. 2024;46(11):877\u201382.","journal-title":"Clin Ther"},{"issue":"38","key":"726_CR17","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2217\/fon-2023-0574","volume":"19","author":"J Nie","year":"2023","unstructured":"Nie J, Wu H, Wu Q, Liu Q, Liu L, Wu J. Cost-effectiveness of BTK inhibitors vs bendamustine and rituximab in chronic lymphocytic leukemia patients. Future Oncol. 2023;19(38):2525\u201336.","journal-title":"Future Oncol"},{"key":"726_CR18","unstructured":"G L. China Guidelines for Pharmacoeconomic Evaluations (2020 Edition). Beijing: People\u2019s Medical Publishing House; 2020."},{"issue":"S2","key":"726_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/hon.3163_154","volume":"41","author":"M Shadman","year":"2023","unstructured":"Shadman M, Munir T, Roback T, Brown JR, Kahl BS, Ghia P, et al. Zanubrutinib versus bendamustine\u2009+\u2009rituximab in patients with treatment-naive CLL\/SLL: extended follow-up of the SEQUOIA study. Hematol Oncol. 2023;41(S2):235\u20138.","journal-title":"Hematol Oncol"},{"issue":"26","key":"726_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018;379(26):2517\u201328.","journal-title":"N Engl J Med"},{"issue":"11","key":"726_CR21","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440\u201350.","journal-title":"Blood Adv"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"726_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR. Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33(6):743\u201354.","journal-title":"Med Decis Mak"},{"issue":"2","key":"726_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.36469\/9896","volume":"2","author":"G Tremblay","year":"2015","unstructured":"Tremblay G, Haines P, Briggs A. A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data. J Health Econ Outcomes Res. 2015;2(2):147\u201360.","journal-title":"J Health Econ Outcomes Res"},{"key":"726_CR25","unstructured":"The Global Health Observatory. Available from: https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/gho-ghe-life-tables-by-country2019."},{"key":"726_CR26","unstructured":"Drug Bidding Price Database. 2024. Available from: https:\/\/db.yaozh.com\/."},{"issue":"5","key":"726_CR27","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","volume":"56","author":"CE Kosmas","year":"2015","unstructured":"Kosmas CE, Shingler SL, Samanta K, Wiesner C, Moss PA, Becker U, et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leuk Lymphoma. 2015;56(5):1320\u20136.","journal-title":"Leuk Lymphoma"},{"key":"726_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-50","volume":"8","author":"KM Beusterien","year":"2010","unstructured":"Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O\u2019Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"726_CR29","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1177\/0272989X11401031","volume":"31","author":"PW Sullivan","year":"2011","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the united Kingdom. Med Decis Mak. 2011;31(6):800\u20134.","journal-title":"Med Decis Mak"},{"issue":"5","key":"726_CR30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","volume":"14","author":"K Tolley","year":"2013","unstructured":"Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749\u201359.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"726_CR31","first-page":"390","volume":"28","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Slack M, Persky D, Andritsos L, Abraham I. Cost-effectiveness and value of information analyses of bruton\u2019s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the united States. J Manag Care Spec Pharm. 2022;28(4):390\u2013400.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"726_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","volume":"23","author":"CS Tam","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23(8):1031\u201343.","journal-title":"Lancet Oncol."},{"key":"726_CR33","doi-asserted-by":"crossref","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018;379(26):2517-28.","DOI":"10.1056\/NEJMoa1812836"},{"key":"726_CR34","doi-asserted-by":"crossref","unstructured":"Kosmas CE, Shingler SL, Samanta K, Wiesner C, Moss PA, Becker U, et al. Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survival. Leuk Lymphoma. 2015;56(5):1320-6.","DOI":"10.3109\/10428194.2014.961012"},{"key":"726_CR35","doi-asserted-by":"crossref","unstructured":"Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O'Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study. Health Qual Life Outcomes. 2010;8:50.","DOI":"10.1186\/1477-7525-8-50"},{"key":"726_CR36","doi-asserted-by":"crossref","unstructured":"Tolley K, Goad C, Yi Y, Maroudas P, Haiderali A, Thompson G. Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. Eur J Health Econ. 2013;14(5):749-59.","DOI":"10.1007\/s10198-012-0419-2"},{"key":"726_CR37","doi-asserted-by":"crossref","unstructured":"Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800-4.","DOI":"10.1177\/0272989X11401031"}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-026-00726-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-026-00726-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:31:56Z","timestamp":1777249916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13561-026-00726-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/s13561-026-00726-y","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This economic analysis was conducted through a literature review and modeling techniques and did not involve the use of individual patient-level data. Therefore, it was considered exempt from approval by Chinese ethics review committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}